Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer

NCT01045538 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT01045538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01045538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer
Lead sponsor
Asan Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2010
Completion date
April 30, 2016
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, histone deacetylase inhibitor